欧州臨床腫瘍学会 (ESMO) 2021 ハイライト

← Back to document page

エンハーツ® DESTINY-Breast03 フェーズ3 データ ... aRapid progressors defined as progression within 6 moof (neo)adjuvant therapy) or 12 if regimen contained pertuzumab. Line of therapy does not include endocrine therapy. bAll patients received at least 1 prior cancer therapy. One patient with prior T -DM1 treatment was enrolled in ...

  Density, Adjuvants